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Abstract
Background: Numerous transcription factors are involved in the establishment and maintenance of the osteoblastic 
phenotype, such as Runx2, osterix and Dlx5. The transcription factor retinoblastoma binding protein-1 (RBP1) was 
recently identified as an estrogen regulated gene in an osteosarcoma cell model. Since the function of RBP1 in 
osteoblastic differentiation and mineralization is unknown, we investigated the role of RBP1 in these processes.
Methods: To create a cell model with suppressed RBP1 expression, primary calvarial osteoblasts were infected with a 
shRNA lentiviral vector specific for mouse RBP1 (CalOB-ΔRBP1) or a scrambled control shRNA lentivirus (CalOB-Control). 
Stable cell lines were generated and their mineralization potential was determined using osteoblastic differentiation 
medium, Alizarin Red staining, and quantitative PCR (QPCR) analyses. Runx2 coactivation by RBP1 was determined 
through the use of transient transfection assays.
Results: Stable expression of the RBP1 shRNA lentivirus in CalOB-ΔRBP1 cells resulted in a 65-70% suppression of RBP1 
expression. Osteoblastic mineralization assays demonstrated that suppression of RBP1 results in a potent delay in 
osteoblastic nodule formation in the CalOB-ΔRBP1 cells with a concomitant decrease in the expression of the 
osteogenic transcription factors Runx2 and osterix, along with decreases in BMP2, alkaline phosphatase, osteocalcin 
and bone sialoprotein. Regulation of Runx2 expression by RBP1 was shown to be mediated through the proximal P2 
Runx2 promoter. Furthermore, RBP1 was demonstrated to be a potent coactivator of Runx2 transcriptional activity on 
two known Runx2 reporter constructs. These data suggest that the expression and activity of Runx2 is critically 
dependent on the presence of RBP1.
Conclusions: This study is the first to demonstrate that RBP1 is an important mediator of the osteoblastic phenotype 
and clearly defines RBP1 as a novel transcription factor involved in the well known Runx2-osterix transcriptional 
cascade. As such, the effects of RBP1 on these processes are mediated through both regulation of Runx2 expression 
and transcriptional activity.
Background
Many transcription factors contribute to the establish-
ment and maintenance of the osteoblastic phenotype,
either directly or indirectly. Some well-known examples
of such transcription factors are Runx2 and osterix. Dele-
tion of either in mice results in a drastic phenotype where
the cartilaginous skeleton fails to ossify, leading to a com-
plete lack of bone [1-4]. Therefore, the identification and
characterization of ancillary transcription factors, which
regulate both the expression and transcriptional function
of these master controller transcription factors (e.g.
Runx2 and osterix), is essential for further understanding
the process of osteoblastic differentiation and developing
future therapeutic interventions to address disorders of
bone metabolism.
Retinoblastoma binding protein-1 (RBP1) is a member
of the AT-rich interaction domain (ARID) superfamily,
also known as ARID4A, that is involved in the repression
of E2F-dependent transcription and cellular proliferation
[5,6] through direct binding with the pocket domain of
retinoblastoma (pRb) [7]. This repressive activity is
largely due to a RBP1-mediated recruitment of mSin3A/
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histone deacetylase (HDAC) complexes to E2F-depen-
dent promoters [8]. More recently, RBP1 deletion in mice
was shown to result in a genomic imprinting defect at the
Prader-Willi syndrome and Angelman syndrome
imprinting center [9] and has been identified as a leuke-
mia suppressor gene in mice [10]. Our laboratory has
recently identified RBP1 as an estrogen-regulated gene in
a U2OS osteosarcoma cell model expressing the estrogen
receptors (ER) ERα and ERβ [11-13].
Although much is known regarding the function of
RBP1 in pRb-mediated suppression of E2F activity, cellu-
lar proliferation, and in epigenetic modifications, nothing
is known regarding the function of RBP1 in osteoblastic
differentiation and function. Therefore, we investigated
the effect of RBP1 suppression on osteoblastic differenti-
ation in primary mouse calvarial osteoblasts. We found
that suppression of RBP1 expression results in a delay in
osteoblastic mineralization with a concomitant decrease
in classic bone marker gene expression. Furthermore, our
data demonstrates that RBP1 supports Runx2 expression
through the use of the Runx2 P2 promoter and serves as a
coactivator of Runx2 activity. This study identifies RBP1
as an important regulator of osteoblastic differentiation
and provides a more comprehensive understanding of the
osteogenic pathway in general.
Methods
Cell Culture and Reagents
Mouse calvarial osteoblast cultures were grown in Mini-
mum Essential Media growth medium (αMEM; Invitro-
gen, Carlsbad, CA) supplemented with 1 × antibiotic/
antimycotic (Invitrogen) and 10% (v/v) fetal bovine
serum. The shRNA-stable mouse calvarial cell cultures,
described in the text, were cultured in the same media
supplemented with 5 mg/L blasticidin S (Boehringer
Mannheim, Indianapolis, IN). For the osteoblast differen-
tiation assays, αMEM growth medium supplemented
with 50 mg/L ascorbic acid and 10 mM β-glycerophos-
phate, termed αMEM differentiation medium, was used.
The human U2OS cell line was cultured in phenol red-
free Dulbecco's Modified Eagle's Medium (DMEM)/F12
media containing 10% (v/v) fetal bovine serum (FBS) and
1 × antibiotic/antimycotic (Invitrogen). Ascorbic acid, β-
glycerophosphate and Alizarin Red were purchased from
Sigma-Aldrich (St. Louis, MO).
Calvarial Osteoblast Preparation
One- to 3-day-old C57BL/6 mouse pups were sacrificed
and the calvaria were minced and digested in Hank's bal-
anced saline solution (Sigma-Aldrich) containing bovine
serum albumin (4 mg/ml) and collagenase type 2 (4 mg/
ml) for 10 min at 37°C. The first two digests were dis-
carded since these mainly contain fibroblasts. The cells
obtained from the third digest were resuspended in
αMEM containing 10% (v/v) fetal bovine serum,
expanded in culture dishes and subsequently used for the
production of the CalOB-Control and CalOB-ΔRBP1 cell
lines used in this study. The study was approved by the
Mayo Clinic Institutional Animal Care and Use Commit-
tee (IACUC #A7909) and performed in accordance with
internationally recognized ethical guidelines.
shRNA Vector Construction and Stable-shRNA Cell Model 
Production
A lentiviral shRNA vector, termed pHREFBL/hU6
(+3276), containing a 21-mer siRNA sequence directed
against +3299 to + 3320 relative to the transcriptional
start site of mouse RBP1 (Accession # NM_001081195),
GACGAGTCCCGAAGTATAAAG, was produced by
America Pharma Source, LLC (Gaithersburg, MD).
Expression of this construct is driven by a U6 promoter
and contains a blasticidin S marker gene for positive
selection of infected cells. A scrambled lentiviral control
vector, containing the same nucleotide bases but in a ran-
dom order, termed pHRBlasdU3-hU6, was also produced
in the same manner. Both lentiviral vectors contain the
loop sequence TTCAAGAGA. Primary mouse calvarial
osteoblast cultures were plated in 24-well dishes at a cell
density of 30-40% in MEM growth medium. The follow-
ing day, 200 ul of either pHREFBL/hU6 (+3276) (RBP1
shRNA) or pHRBlasdU3-hU6 (Scrambled Control
shRNA) lentiviral vector was added to each well and
allowed to incubate at 37°C overnight. The viral stock
media was then replaced with MEM growth medium for
an additional 48 h. To select for stable lentiviral infection,
5 mg/L blasticidin S-containing growth medium was
added to the cells for a 4 day selection period, changing
the selection medium at 2 days. Each well was subcul-
tured into T-75 culture flasks and the cells were main-
tained in αMEM supplemented with 5 mg/L blasticidin S.
The resulting primary mouse calvarial shRNA cell cul-
tures were termed CalOB-Control and CalOB-ΔRBP1.
The experiments described in this manuscript were per-
formed three times using independent calvarial cell prep-
arations with similar results. Representative experiments
are shown.
Proliferation Assay
The CalOB-Control and CalOB-ΔRBP1 cell lines were
seeded in growth medium into 96-well plates at a density
of 6400 cells per well (2 × 104 cells/cm2) and allowed to
proliferate (n = 6) for 72 hours. Twenty microliters of the
Cell Titer 96 Aqueous One Solution Cell Proliferation
Assay (Promega, Madison, WI) were added to each well
and allowed to incubate at 37°C for 30 minutes. The plate
was read at 490 nM on a SpectraMax 340 spectropho-
tometer (Molecular Devices Corp., Sunnyvale, CA) using
the SoftMax Pro software (Molecular Devices Corp.).Monroe et al. BMC Musculoskeletal Disorders 2010, 11:104
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Differentiation Analyses and Alizarin Red Staining
The CalOB-Control and CalOB-ΔRBP1 cell lines were
plated at approximately 50% confluence (1.3 × 104 cells/
cm2) in 12-well dishes and allowed to reach confluence.
At that time, αMEM differentiation media was added to
the cells and changed every 3 days. Cells were harvested
in triplicate for RNA at 0, 10, 17 and 31 days of culture
using Trizol Reagent (Invitrogen). Parallel triplicate wells
were stained for calcified bone nodules using Alizarin
R ed (S igm a-A ldric h) .  Bri efl y ,  c e l ls  we r e  was hed in 1 ×
PBS and fixed in 3.75% paraformaldehyde overnight at
room temperature. Following two 1 × PBS washes, the
cells were stained with 1.2% Alizarin Red (v/v) ph 4.2 for
20 min. The cells were extensively washed with 1 × PBS
and subsequently scanned.
Reverse Transcription PCR (RT-PCR) Analyses
Total RNA was harvested using TRIzol reagent following
the manufacturers protocol (Invitrogen). One microgram
(μg) of RNA was used in a reverse transcriptase (RT)
reaction using the iScript cDNA Synthesis Kit (Biorad,
Hercules, CA) according to manufacturer instructions.
The RT reactions were diluted 1:5 and 2 μl used for real-
time quantitative PCR (QPCR) using the Biorad iCycler
(Biorad) and the iQ SYBR Green Supermix reaction kit
(Biorad). Fold changes in gene expression were calculated
as 2(Housekeeping Ct - Gene Ct), where the housekeeping gene
was TATA-binding protein (TBP). The primer sequences
used in this study can be found in Table 1.
Transient Transfection Analyses
U2OS or primary mouse calvarial osteoblast cells were
plated at a density of 50% (2.6 × 104 and 1.3 × 104 cells/
cm2, respectively) in 12-well plates the day before trans-
fection. Two-hundred and fifty (250) ng of the p6OSE2-
Luc reporter construct [14], or the mouse osteocalcin
reporter construct [14], along with Runx2 [1] and RBP1
[15] expression constructs, were transiently transfected
in triplicate using FuGENE 6 transfection reagent (Roche
Diagnostics, Indianapolis, IN) for the U2OS cells or Lipo-
fectamine LTX Reagent (Invitrogen) for the calvarial
osteoblasts according to the manufacturer's instructions.
Following incubation at 37°C for 48 hours, cells were har-
vested in 1 × Passive Lysis Buffer (Promega) and equal
quantities of protein extracts were assayed using
Luciferase Assay Reagent (Promega).
Results
Generation of a mouse calvarial osteoblast cell model with 
suppressed RBP1 expression
Numerous transcription factors are involved in the estab-
lishment and maintenance of osteoblastic differentiation
such as Runx2, osterix and Dlx5 [16]. We have previously
identified RBP1 as an estrogen regulated gene in U2OS
osteosarcoma cells stably expressing ERα [11-13], how-
ever, no information exists on the function of RBP1 dur-
ing the process of osteoblastic differentiation. As an
initial step in understanding the role of RBP1 in this pro-
cess, we generated a primary osteoblastic cell model in
which RBP1 expression was reduced. A shRNA lentiviral
expression vector was generated against the mouse RBP1
sequence and introduced into primary mouse calvarial
osteoblasts (Figure 1A). A scrambled sequence control
lentivirus was also generated and infected in an identical
manner to serve as a control for non-specific effects of
the viral infection. Following antibiotic selection, cell
lines stably expressing the mouse RBP1 shRNA (CalOB-
ΔRBP1) or the scrambled control shRNA (CalOB-Con-
trol) were established. Quantitative PCR (QPCR) analysis
indicated a 65-70% reduction in RBP1 expression in
CalOB-ΔRBP1 cells when compared to the CalOB-Con-
trol cell line (Figure 1B), demonstrating successful RBP1
suppression. A proliferation assay was performed on the
CalOB-Control and CalOB-ΔRBP1 cell lines since RBP1
has been implicated in cell cycle regulation [5,6], however
no difference in proliferative capacity of these cells was
observed (Figure 1C).
Effect of RBP1 suppression on osteoblastic differentiation 
and bone marker gene expression
To determine the role of RBP1 in the establishment of the
osteoblastic phenotype, the CalOB-ΔRBP1 and CalOB-
Control cell lines were tested for the ability to form min-
eralized nodules when cultured in osteoblastic differenti-
ation media for 10, 17 and 31 days of culture. As
expected, mineralized bone nodules were observed fol-
lowing 10 days of culture in the CalOB-Control cell line
with significant mineralization observed at 17 and 31
days of culture (Figure 2A). In contrast, only at 31 days of
culture were mineralized nodules observed in the CalOB-
ΔRBP1 cell line (Figure 2B), demonstrating a significant
delay in the onset of osteoblastic differentiation following
RBP1 suppression. Figure 2C shows that RBP1 expression
remained low throughout the differentiation time-course
in the CalOB-ΔRBP1 cell line. Interestingly, RBP1 expres-
sion increased approximately 1.8-fold during the course
of differentiation in the control cell line suggesting that its
expression is both regulated and important for this pro-
cess.
Since RBP1 suppression resulted in a significant delay
in mineralized nodule formation, we next determined
whether bone marker gene expression followed a similar
pattern of suppression. CalOB-ΔRBP1 and CalOB-Con-
trol cells were treated identically as in Figure 2 and ana-
lyzed for bone marker gene expression using QPCR. As
shown in Figure 3A and 3B, the transcription factors
Runx2 and osterix, both necessary for bone formation
bone [1-4], are significantly suppressed in the CalOB-Monroe et al. BMC Musculoskeletal Disorders 2010, 11:104
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ΔRBP1 cell line and either do not increase, or only
increase slightly during the differentiation process. Fur-
thermore, as seen in Figure 3C-F, the classic bone marker
genes bone morphogenetic protein-2 (BMP2), alkaline
phosphatase, osteocalcin and bone sialoprotein (BSP), are
also significantly suppressed in the CalOB-ΔRBP1 cell
line. As with Runx2 and osterix, increased expression of
these genes is only observed at the 31 day timepoint when
the first signs of mineralization are observed in the
CalOB-ΔRBP1 cell line (Figure 2B). This data unequivo-
cally demonstrates that suppression of RBP1 expression
in primary mouse calvarial osteoblasts results in a signifi-
cant delay in osteoblastic mineralization with a concomi-
tant suppression of bone marker gene expression. These
data also reveal a novel and necessary role for RBP1 in the
establishment of the osteoblastic phenotype.
RBP1 regulation of Runx2 expression and transcriptional 
function
Runx2 is an essential mediator of the osteoblastic pheno-
type, as Runx2 deletion in mouse knockout models
results in a complete elimination of mineralized bone [1-
3]. Expression of Runx2 is controlled by two independent
promoters, a distal P1 promoter and a proximal P2 pro-
moter, which are largely regulated through distinct mech-
anisms [17]. Since suppression of RBP1 results in a
significant decrease in Runx2 expression, we used prim-
ers specific for Runx2 transcripts arising from the P1 and
P2 promoters in a QPCR analysis. As is shown in Figure
4, only transcripts arising from the P2 promoter, which
are largely controlled through epigenetic mechanisms
such as methylation [17], are suppressed following RBP1
depletion, demonstrating Runx2 promoter specificity in
RBP1 function.
Although little is known regarding the function of
RBP1 in osteoblasts, its role as a retinoblastoma tran-
scriptional coregulator is well known. Most of the mem-
bers of the ARID transcription factor superfamily,
including RBP1/ARID4A, weakly bind DNA without
sequence specificity and primarily influence gene expres-
sion through protein-protein interactions [18]. Therefore,
it is conceivable that RBP1 also acts as a coregulator of
osteogenic transcription factors, such as Runx2. In order
to assess the role of RBP1, if any, in coregulation of Runx2
activity, transient transfection analyses were conducted
using two known Runx2-responsive luciferase reporter
constructs, p6OSE2-Luc [14] and the mouse osteocalcin
promoter [14]. As seen in Figure 5A, transient transfec-
tion of Runx2 alone into mouse calvarial osteoblasts
resulted in a modest activation of the p6OSE2-Luc and
the mouse osteocalcin reporter constructs, respectively.
Table 1: Primer sequences for quantitative PCR (QPCR) used in this study
Gene/Symbol Accession # Orientation Mouse-Specific Primer Sequences (5' to 3')
RBP1 NM_001081195 Forward GCAAAAGACGAACCCCAAAGCGGAC
Reverse TCCTGCGTGAGACACTTCTCTGTC
Runx2 NM_009820 Forward GCCGGGAATGATGAGAACTA
Reverse GGTGAAACTCTTGCCTCGTC
Osterix NM_130458 Forward GGAGGTTTCACTCCATTCCA
Reverse TAGAAGGAGCAAGGGGACAGA
BMP2 NM_007553 Forward ACGTCCTCAGCGAATTTGAG
Reverse GCCTGCGGTACAGATCTAGC
Osteocalcin NM_007541 Forward GCCATCACCCTGTCTCCTAA
Reverse GCTGTGGAGAAGACACACGA
Alkaline Phos. NM_007431 Forward TGAGCGACACGGACAAGA
Reverse GGCCTGGTAGTTGTTGTGAG
BSP NM_008318 Forward TTCCCAGGTGTGTCATTGAAGA
Reverse GGTATGTTTGCGCAGTTAGCAA
TBP NM_013684 Forward GCACTTCGTGCAAGAAATGCTG
Reverse CATAGCTCTTGGCTCCTGTGC
Runx2: P1 N/A Forward CCGGCCACTTCGCTAACTT
Reverse TGGTGCTCGGATCTACAGGAA
Runx2: P2 N/A Forward TCTGGAAAAAAAAGGAGGGACTATG
Reverse GGTGCTCGGATCCCAAAAGAAMonroe et al. BMC Musculoskeletal Disorders 2010, 11:104
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Figure 1 shRNA design and confirmation of RBP1 knockdown in mouse calvarial osteoblasts. (A) The sequence at +3299 to +3320 relative to 
the start of transcription of mouse RBP1 gene was selected and packaged into a shRNA lentiviral expression vector along with a scrambled shRNA 
control. Both lentiviral constructs were infected into wild-type mouse calvarial osteoblasts and stable cell lines were selected using blasticidin S for 2 
weeks. The resulting cell lines are termed CalOB-Control and CalOB-ΔRBP1. (B) Total RNA from the CalOB-Control and CalOB-ΔRBP1 cell lines (n = 3) 
were isolated and processed for real-time QPCR analysis. The data are expressed as RBP1 expression relative to TBP controls and normalized to the 
CalOB-Control cell line. (C) The CalOB-Control and CalOB-ΔRBP1 cell lines were plated (n = 6), allowed to grow for 72 hours and a proliferation assay 
was performed. The data are expressed as relative cellular proliferation normalized to the CalOB-Control cell line. For all panels, the black bars represent 
the mean ± standard deviation. The asterisk represents statistical significance at the p < 0.01 level (ANOVA).
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RBP1 alone did not alter the activity of either reporter
construct; however coexpression of Runx2 and RBP1
resulted in a potent coactivation of both reporter con-
structs (8-fold and 2-fold). To verify the coactivation of
Runx2 by RBP1 in an independent cell system, the same
experiment was performed in the human U2OS osteosar-
coma cell line (Figure 5B). As was observed in the mouse
calvarial cells, expression of Runx2 alone resulted in a sta-
tistically significant 13-fold and 4-fold activation of the
p6OSE2-Luc and the mouse osteocalcin reporter con-
structs. Coexpression of Runx2 and RBP1 resulted in a
synergistic activation, 140-fold and 10.5-fold respectively,
of the two reporter constructs. In combination, these
data demonstrate that RBP1 not only regulates Runx2
expression, but also acts as a potent coactivator of Runx2
transcriptional function in two independent cell systems.
Discussion
The objective of this study was to expand on our previous
identification of RBP1 as a novel estrogen target gene in
osteoblasts [11-13] by determining its role in the process
of osteoblastic differentiation. We approached this inter-
esting question through the production of a novel cell
model where a lentiviral shRNA was stably introduced
into primary mouse calvarial osteoblast cells. These cells
exhibited a striking delay in the onset of mineralized nod-
ule formation with a simultaneous suppression of bone
marker genes such as Runx2, osterix, alkaline phos-
phatase, bone sialoprotein, osteocalcin and bone mor-
phogenetic protein-2 (BMP2). This result is very similar
to Runx2 -/- cells, which also exhibit deficiencies in the
expression of these bone marker genes [2], suggesting
that RBP1 may play a direct role in the normal expression
and function of Runx2. This leads to the interesting
notion that the osteogenic role of RBP1 is likely to be
mediated, at least in part, by Runx2.
Runx2 is an important osteoblast lineage-determining
transcription factor involved in directing precursor stem
cells to the preosteoblast lineage and their concomitant
differentiation [19]. Runx2 appears to be the master gene
Figure 2 Alizarin Red staining reveals a significant delay in osteoblastic mineralization of the CalOB-ΔRBP1 cell line. The CalOB-Control (A) 
and CalOB-ΔRBP1 (B) cell lines were plated (n = 3) and allowed to differentiate in osteoblastic differentiation media for 0, 10, 17 and 31 days. The cells 
were subsequently stained using Alizarin Red. (C) Total RNA was extracted from identically treated CalOB-Control (solid line) and CalOB-ΔRBP1 (dotted 
line) cells and processed for real-time QPCR analysis (n = 3). The data are expressed as RBP1 expression relative to a TBP control and normalized to the 
day 0 CalOB-Control cell line. The data points represent the mean ± standard deviation. The asterisks represents statistical significance at the p < 0.01 
level (ANOVA).
* * * *Monroe et al. BMC Musculoskeletal Disorders 2010, 11:104
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for osteoblast differentiation [14,20-22] as it induces the
expression of osterix, a transcription factor which is
required to finalize terminal osteoblast differentiation [4].
In addition, Runx2 plays a role in many other osteoblast
functions such as activation of genes encoding osteocal-
cin, bone sialoprotein, osteopontin, and type 1 collagen
and is also involved in autoregulation [2,3]. Mice lacking
Runx2 and osterix have only a cartilaginous skeleton due
to the lack of differentiated osteoblasts and die shortly
after birth [1-4]. Furthermore, mutations in the Runx2
gene are found in patients with the human disorder
Cleidocranial Dysplasia [23]. The data in this paper pro-
vide evidence that RBP1 plays an important role in regu-
lating Runx2 expression and coactivation of Runx2-
dependent bone marker genes, thus establishing RBP1 as
an important mediator of Runx2 action in osteoblasts.
Recently a knock-out mouse model for RBP1 has been
developed [9]. These mice display suppressed epigenetic
modifications (e.g. chromatin/nucleosome methylation)
at the PWS/AS genetic domain involved in Prader-Willi
and Angelman Syndromes. In conjunction with this
observation, we determined that RBP1 suppression
Figure 3 Real-time QPCR analysis demonstrates suppressed bone marker gene expression in the CalOB-ΔRBP1 cell line. Total RNA was ex-
tracted from CalOB-Control (solid line) and CalOB-ΔRBP1 (dotted line) cells treated as in Figure 2 and processed for real-time QPCR analysis (n = 3) for 
the indicated genes (A-F). The data are expressed as target gene expression relative to TBP controls and normalized to the day 0 CalOB-Control cell 
line. The data points represent the mean ± standard deviation. The asterisks represents statistical significance at the p < 0.01 level (ANOVA).
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decreases the amount of transcript arising from the
Runx2 P2 promoter. Analysis of the Runx2 P2 promoter
revealed a large CpG island extending from the P2 pro-
moter to the 5' untranslated region of exon 1 of Runx2
[17], suggesting epigenetic modifications may be an
important regulatory component of Runx2 P2-promoter-
dependent activity. Another CpG island is located near
the 3' end of the Runx2 gene [17], further suggesting that
epigenetic modification may be an important regulatory
facet of Runx2 regulation. This evidence demonstrating
Figure 5 RBP1 is a Runx2 coactivator in both U2OS osteosarcoma and mouse calvarial osteoblast cell models. Mouse calvarial osteoblast (A) 
or human U2OS osteosarcoma (B) cells were transiently transfected (n = 3) with either the p6OSE2-Luc reporter construct or the mouse osteocalcin 
luciferase reporter construct as described under "Methods." The black bars represent the mean ± standard deviation. A single asterisk (*) represents 
significance of p < 0.01 (ANOVA) relative to the reporter construct alone and a double asterisk (**) represents significance of p < 0.01 (ANOVA) relative 
to the reporter and Runx2 expression construct alone. U.D. stands for undetectable.
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that RBP1 is involved in the modulation of epigenetic
processes, along with our data demonstrating RBP1 regu-
lation of the Runx2 P2 promoter, which is known to be
regulated by epigenetic processes, is intriguing. Whether
RBP1 directly regulates these processes at the Runx2 P2
promoter requires further experimentation.
Conclusions
In its entirety, this paper presents evidence that the RBP1
transcription factor plays an important role in osteoblast
biology since its suppression in primary mouse calvarial
osteoblasts results in a striking delay in mineralization
and suppression of well-known osteoblast marker genes.
We further demonstrate that RBP1 regulates Runx2
expression through the proximal P2 promoter, a pro-
moter known to be a target of epigenetic modifications,
s u c h  a s  m e t h y l a t i o n .  I n t e r e s t i n g l y ,  w e  a l s o  i d e n t i f i e d
RBP1 as a potent transcriptional coactivator of Runx2
transcriptional activity. This underscores a dualism in the
effects of RBP1 on Runx2, both through the maintenance
of Runx2 expression as well as transcriptional coactiva-
tion. These important observations are the first to sug-
g e s t  a  r o l e  f o r  R B P 1  i n  p r o c e s s e s  o t h e r  t h a n  c e l l
proliferation, and could open up novel approaches for the
modulation of Runx2 activity in both in vitro and in vivo
models of osteoblast function.
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